Corsa P, Parisi S, Canistro A, Raguso A, Fusco V, Troiano M, Bucci F, Mastrodonato N, Tardio B
Ospedale I.R.C.C.S. Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia.
Radiol Med. 1997 Dec;94(6):658-63.
From March, 1988, to October, 1993, fifty-six consecutive patients with rectal adenocarcinoma in clinical stage T3NxM0, underwent preoperative radiation therapy at the "Casa Sollievo della Sofferenza" Hospital of San Giovanni Rotondo (Italy). The patients were treated with the four-field technique with 6 to 8 MV X photons on the pelvis. The dose given was 36 Gy in 12 fractions of 3 Gy each. Surgery was performed 2-3 weeks after completion of radiotherapy. Six patients were excluded from this study for metastatic involvement of the liver found at surgery. 48% of 50 assessable patients underwent abdominoperineal resection and 52% anterior resection. 68% of patients were in pathologic stage pT0-3 pN0 and 32% in pT0-3 pN1-2. Metastatic nodes were found in 16 patients (32%) (11 pN1 and 5 pN2). 4% of patients achieved a complete response. The follow-up ranged 24 to 91 months (mean: 46 months). None of the 50 patients died during the postoperative period and the specific morbidity was 26%. Side-effects, requiring surgery, were found in 4% of patients (1 retroperitoneal fibrosis and 1 small bowel occlusion). The incidence of local relapse was 8%. The overall survival at 5 years, in all stages, calculated with the Kaplan and Meyer method, was 76.5%. The disease-free survival rate was 81.1% in all stages: 94.1% in pT0-3 pN0 patients and 54.1% in pT0-3 pN1-2 patients. The disease-free survival rate related to nodal involvement was 72.7% in pN1 patients and 20% in pN2 patients. Our experience confirms the effectiveness of preoperative radiation therapy to improve local control in rectal cancer patients. In the future, it will be useful to assess the impact on prognosis of the schedules using chemotherapy, different fractionation of radiotherapy, delayed surgery and biological predictors of response to irradiation.
1988年3月至1993年10月,56例临床分期为T3NxM0的直肠腺癌患者在意大利圣乔瓦尼-罗通多的“索列沃-德拉-索费伦扎之家”医院接受了术前放射治疗。患者采用四野技术,使用6至8兆伏的X线光子对骨盆进行照射。给予的剂量为36戈瑞,分12次,每次3戈瑞。放疗结束后2至3周进行手术。6例患者因手术中发现肝脏转移而被排除在本研究之外。50例可评估患者中,48%接受了腹会阴联合切除术,52%接受了前切除术。68%的患者病理分期为pT0 - 3 pN0,32%为pT0 - 3 pN1 - 2。16例患者(32%)发现有转移淋巴结(11例pN1和5例pN2)。4%的患者达到完全缓解。随访时间为24至91个月(平均46个月)。50例患者术后均无死亡,特定发病率为26%。4%的患者出现需要手术治疗的副作用(1例腹膜后纤维化和1例小肠梗阻)。局部复发率为8%。采用Kaplan - Meyer方法计算,所有分期患者的5年总生存率为76.5%。所有分期的无病生存率为81.1%:pT0 - 3 pN0患者为94.1%,pT0 - 3 pN1 - 2患者为54.1%。pN1患者与淋巴结受累相关的无病生存率为72.7%,pN2患者为20%。我们的经验证实了术前放射治疗对改善直肠癌患者局部控制的有效性。未来,评估化疗方案、不同放疗分割方式、延迟手术以及放疗反应的生物学预测指标对预后的影响将是有益的。